BioNTech SE (BNTX) EBIT Margin (2018 - 2025)

BioNTech SE has disclosed EBIT Margin across 8 years of filings, most recently posting 35.57% for Q4 2025.

• EBIT Margin for Q4 2025 came in at 35.57%, down 3558.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 54.43% (down 5439.0% YoY), and the FY2025 annual result was 1870.71%, down 182293.0% from the prior year.
• EBIT Margin came in at 35.57% for Q4 2025 at BioNTech SE, down from 3.09% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 84.95% in Q4 2021 to a low of 6424.36% in Q2 2025.
• The 5-year median for EBIT Margin is 21.87% (2023), against an average of 732.83%.
• Peak annual rise in EBIT Margin reached 321089 bps in 2025, while the deepest fall reached 567362 bps in 2025.
• BioNTech SE's EBIT Margin stood at 84.95% in 2021, then declined by 9 bps to 76.97% in 2022, then plunged by 54 bps to 35.58% in 2023, then sank by 100 bps to 0.0% in 2024, then sank by 790105 bps to 35.57% in 2025.
• The last three EBIT Margin figures came in at 35.57% (Q4 2025), 3.09% (Q3 2025), and 6424.36% (Q2 2025), per Business Quant data.